{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.35","upperLimit":"1.54","value":"1.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Time to disease progression is defined as the time from registration to the earliest date of documented disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had tumor progression at the time of their death","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.","id":"OG000","title":"Bortez/Cyc/Dex"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of Study (up to 5 years)","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"Months"}